Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 46Lung Neoplasms 19Melanoma 18Neoplasm Metastasis 16Carcinoma, Hepatocellular 15Neoplasms 13Esophageal Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Colorectal Neoplasms 9Breast Neoplasms 9Head and Neck Neoplasms 8Stomach Neoplasms 6Rectal Neoplasms 6Esophageal Squamous Cell Carcinoma 6Carcinoma, Renal Cell 6Brain Neoplasms 6Small Cell Lung Carcinoma 5Recurrence 5Pancreatic Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Liver Neoplasms 4Glioblastoma 4Cholangiocarcinoma 4Prostatic Neoplasms 3Nasopharyngeal Carcinoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3

Interventions

pembrolizumab 91Gemcitabine 56Nivolumab 50Cisplatin 39atezolizumab 37Carboplatin 30avelumab 29enfortumab vedotin 25Docetaxel 23Magnetic Resonance Spectroscopy 19Mitomycin 17Ipilimumab 17Paclitaxel 16Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Immunotherapy × Clear all
NCT06120374 2025-12-30

Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC

Peking University First Hospital

Recruiting
178 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05229614 2024-08-21

ICONIC

CNAO National Center of Oncological Hadrontherapy

Phase 2 Recruiting
27 enrolled
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma

NCT03115801 2021-09-22

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Weill Medical College of Cornell University

Phase 2 Terminated
6 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡